Dimethylamine

Dimethylamine

SCHEMBL4134839

C=Cn1cnc2c(NCC)ncnc21.CNC

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.51
ADORA3 P0DMS8 1/20 0.47
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TMIGD3 P0DMS9 4/20 0.42
ADORA2A P29274 4/20 0.42
ADORA1 P30542 4/20 0.42
ADORA2B P29275 1/20 0.42
YTHDC1 Q96MU7 2/20 0.42
KDM4E B2RXH2 1/20 0.41
CDK1 P06493 4/20 0.41
CCNB2 O95067 3/20 0.41
CCNB1 P14635 3/20 0.41
CCNB3 Q8WWL7 3/20 0.41
CDK2 P24941 1/20 0.38
KMT2A Q03164 1/20 0.38
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL4143569 0.89 SRC (0.49) SRCADORA3RAB9ANPC1HPGD
SCHEMBL4120821 0.83 YTHDC1 (0.60) SRCADORA3RAB9ANPC1HPGD
SCHEMBL4134836 0.80 SRC (0.48) SRCRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL4143566 0.78 SRC (0.46) SRCRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL20857256 0.75 YTHDC1 (0.67) ADORA3RAB9ANPC1TMIGD3ADORA2A
SCHEMBL28252163 0.74 ADORA3 (0.49) ADORA3TMIGD3ADORA2AADORA1ADORA2B
SCHEMBL28251685 0.74 ADORA3 (0.49) ADORA3RAB9ATMIGD3ADORA2AADORA1
SCHEMBL28252201 0.74 ADORA3 (0.49) ADORA3TMIGD3ADORA2AADORA1ADORA2B
SCHEMBL4128648 0.72 ADORA1 (0.56) SRCADORA3ADORA2AADORA1ADORA2B
SCHEMBL26354839 0.72 CDK1 (0.72) ADORA3NPC1ADORA2AADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586566-B2 Unsaturated heterocyclic derivatives ARIAD PHARMACEUTICALS, INC. (US) 2013-11-19 US disclosed
US-20120178716-A1 Unsaturated Heterocyclic Derivatives ARIAD PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
US-8071609-B2 Unsaturated heterocyclic derivatives ARIAD PHARMACEUTICALS, INC. (US) 2011-12-06 US disclosed
US-20090156596-A1 Unsaturated Heterocyclic Derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156596-A1 Unsaturated Heterocyclic Derivatives CYP2F1, CYP2J2, ALOX5 SRC 4651/4885ADORA3 2445/4885RAB9A 3985/4885
US-20120178716-A1 Unsaturated Heterocyclic Derivatives CYP2F1, CYP2J2, ALOX5 SRC 4651/4885ADORA3 2445/4885RAB9A 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.